Gene · 9113
Papers3,081
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 3,081
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hippo Pathway Activation in Aged Mesenchymal Stem Cells Contributes to the Dysregulation of Hepatic Inflammation in Aged Mice. | Adv Sci (Weinh) | 2023 | 37544916 | PubTator, text mining | PubMed |
| Cardiomyocyte proliferation is suppressed by ARID1A-mediated YAP inhibition during cardiac maturation. | Nat Commun | 2023 | 37543677 | PubTator, text mining | PubMed |
| TAZ upregulates MIR-224 to inhibit oxidative stress response in multiple myeloma. | Cancer Rep (Hoboken) | 2023 | 37539777 | PubTator, text mining | PubMed |
| LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling. | Mol Cancer | 2023 | 37537569 | PubTator, text mining | PubMed |
| Mapping the MOB proteins' proximity network reveals a unique interaction between human MOB3C and the RNase P complex. | J Biol Chem | 2023 | 37536630 | PubTator, text mining | PubMed |
| Searching for Novel Biomarkers in Thymic Epithelial Tumors: Immunohistochemical Evaluation of Hippo Pathway Components in a Cohort of Thymic Epithelial Tumors. | Biomedicines | 2023 | 37509515 | PubTator, text mining | PubMed |
| GPR81-mediated reprogramming of glucose metabolism contributes to the immune landscape in breast cancer. | Discov Oncol | 2023 | 37500811 | PubTator, text mining | PubMed |
| Serine/Threonine Protein Kinase-3 Promotes Oral Squamous Cell Carcinoma by Activating Ras-MAPK Mediated Cell Cycle Progression. | Int J Gen Med | 2023 | 37496599 | PubTator, text mining | PubMed |
| Signaling pathways governing the maintenance of breast cancer stem cells and their therapeutic implications. | Front Cell Dev Biol | 2023 | 37492224 | PubTator, text mining | PubMed |
| A concise review on the role of MIR100HG in human disorders. | J Cell Mol Med | 2023 | 37487022 | PubTator, text mining | PubMed |
| RGS16 regulates Hippo-YAP activity to promote esophageal cancer cell proliferation and migration. | Biochem Biophys Res Commun | 2023 | 37473526 | PubTator, text mining | PubMed |
| Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies. | Front Oncol | 2023 | 37469419 | PubTator, text mining | PubMed |
| [Doublecortin-like kinase 1 activates Hippo pathway to promote migration, invasion and proliferation of pancreatic cancer cells]. | Zhonghua Zhong Liu Za Zhi | 2023 | 37462016 | PubTator, text mining | PubMed |
| MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way. | Hepatol Int | 2023 | 37460832 | PubTator, text mining | PubMed |
| PLAGL2 promotes bladder cancer progression via RACGAP1/RhoA GTPase/YAP1 signaling. | Cell Death Dis | 2023 | 37454211 | PubTator, text mining | PubMed |
| Cyclophilin A Isomerisation of Septin 2 Mediates Abscission during Cytokinesis. | Int J Mol Sci | 2023 | 37446263 | PubTator, text mining | PubMed |
| The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment. | Cancers (Basel) | 2023 | 37444578 | PubTator, text mining | PubMed |
| Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance. | Cancers (Basel) | 2023 | 37444501 | PubTator, text mining | PubMed |
| Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies. | MedComm (2020) | 2023 | 37441462 | PubTator, text mining | PubMed |
| Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma. | Front Toxicol | 2023 | 37441092 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9113/papers?page=18